Francesco Bertoni

Prof. Dr. Francesco Bertoni

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2005 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
GNGiorgio Napolitani
Giorgio Napolitani
ARAndrea Rinaldi
Andrea Rinaldi
Francesco BertoniFrancesco Bertoni
Francesco Bertoni
FSFederica Sallusto
Federica Sallusto
ALAntonio Lanzavecchia
Antonio Lanzavecchia

3 May 2009 in Nature
Verified
Journal Article
Closed access
PDF file
MCMara Compagno
Mara Compagno
WLWei Keat Lim
Wei Keat Lim
AGAdina Grunn
Adina Grunn
SNSubhadra V. Nandula
Subhadra V. Nandula
MBManisha Brahmachary
Manisha Brahmachary
LPLaura Pasqualucci
Laura Pasqualucci

13 June 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
GFGiulia Fabbri
Giulia Fabbri
SRSilvia Rasi
Silvia Rasi
DRDavide Rossi
Davide Rossi
VTVladimir Trifonov
Vladimir Trifonov
HKHossein Khiabanian
Hossein Khiabanian
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano
The pathogenesis of chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is still largely unknown. The full spectrum of genetic lesions that are present in the CLL genome, and therefore the number and identity of dysregulated cellular pathways, have not been identified. By combining next-generation sequencing and copy number analysis, we show here that the typical CLL coding genome contains <20 clonally represented gene alterations/case, including predominantly nonsilent mutations, and fewer copy number aberrations. These analyses led to the discovery of several genes not previously known to be altered in CLL. Although most of these genes were affected at low frequency in an expanded CLL screening cohort, mutational activation of NOTCH1, observed in 8.3% of CLL at diagnosis, was detected at significantly higher frequency during disease progression toward Richter transformation (31.0%), as well as in chemorefractory CLL (20.8%). Consistent with the association of NOTCH1 mutations with clinically aggressive forms of the disease, NOTCH1 activation at CLL diagnosis emerged as an independent predictor of poor survival. These results provide initial data on the complexity of the CLL coding genome and identify a dysregulated pathway of diagnostic and therapeutic relevance.

21 February 2013 in Blood
Verified
Journal Article
Open access
PDF file
DRDavide Rossi
Davide Rossi
SRSilvia Rasi
Silvia Rasi
VSValeria Spina
Valeria Spina
ABAlessio Bruscaggin
Alessio Bruscaggin
SMSara Monti
Sara Monti
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano
Key Points: The integration of mutations and cytogenetic lesions improves the accuracy of survival prediction in chronic lymphocytic leukemia.

1 January 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ASAnastasios Stathis
Anastasios Stathis
Francesco BertoniFrancesco Bertoni
Francesco Bertoni
Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression and are involved in cancer pathogenesis. Over the last years, several BET inhibitors have been developed and clinically tested. Results from the first clinical trials show limited single-agent activity in a small subset of patients with hematologic malignancies and in NUT carcinoma. Adverse events have been observed and may limit treatment compliance. Here, we review the preclinical rationale for targeting BET proteins in cancer and the preliminary results from clinical trials, and outline future directions for the use of BET inhibitors as antitumor agents. Significance: BET inhibitors represent a new class of anticancer agents. Results from the first clinical trials confirm the antitumor potential of BET inhibitors, but their efficacy as single agents seems to be limited. Based on preclinical data, combination therapies with other anticancer agents and the development of a new generation of compounds may open new possibilities for targeting BET proteins as effective anticancer strategies. Cancer Discov; 8(1); 24–36. ©2017 AACR.

1 April 2015 in Cancer Cell
Verified
Journal Article
Closed access
RCRamona Crescenzo
Ramona Crescenzo
FAFrancesco Abate
Francesco Abate
ELElena Lasorsa
Elena Lasorsa
FTFabrizio Tabbo’
Fabrizio Tabbo’
MGMarcello Gaudiano
Marcello Gaudiano
GIGiorgio Inghirami
Giorgio Inghirami